Expert Interview
Discussing FDA Accelerated Approval for Bayer's Sevabertinib (Hyrnuo) for HER2-Mutant Non-Squamous NSCLC
Ticker(s): BAYRYDr. Nicolas Girard
Institution: Institut Curie
- Full Professor and Pneumologist directing the Curie-Montsouris Thorax Institute and Medical Oncology Department at Institut Curie, specializing in thoracic oncology.
- Coordinator for over 50 clinical trials, advancing treatments for lung cancer and rare thymic tumors, notably through the RYTHMIC network and EURACAN.
- ESMO member and Versailles Saint Quentin University professor, authoring over 300 peer-reviewed publications in leading oncology journals.
Are You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Dec 15, 2025
- Call Time
- 10:00 AM EST
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
